Stocktoria
VYNE Therapeutics Inc. VYNE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-01-25
VYNE Therapeutics Inc. insider transactions (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Domzalski David | PRESIDENT AND CEO | 2026-05-29 | Grant | 30,791 | $0.31 |
| Zeronda Tyler | CHIEF FINANCIAL OFFICER | 2026-03-31 | Tax withheld | 4,007 | $0.60 |
| Stuart Iain | CHIEF SCIENTIFIC OFFICER | 2026-03-31 | Tax withheld | 2,876 | $0.60 |
| Harsch Mutya | CHIEF LEGAL OFFICER AND GC | 2026-03-31 | Tax withheld | 4,007 | $0.60 |
| Domzalski David | PRESIDENT AND CEO | 2026-03-31 | Tax withheld | 14,232 | $0.60 |
| Domzalski David | PRESIDENT AND CEO | 2025-12-31 | Tax withheld | 12,684 | $0.58 |
| Zeronda Tyler | CHIEF FINANCIAL OFFICER | 2025-12-31 | Tax withheld | 7,858 | $0.58 |
| Stuart Iain | CHIEF SCIENTIFIC OFFICER | 2025-12-31 | Tax withheld | 2,448 | $0.58 |
Source: SEC EDGAR filings · CIK 0001566044 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.